Brainsway

Company Overview

Snapshot

Founded in January 2003 by Avner Hagai, Yiftach Roth, David Zacut, and Abraham Zangen, Brainsway operates with 51–200 employees. The company has raised $79.95 million across six funding rounds from six investors. In September 2024, BrainsWay announced a US$20 million private placement with Valor Equity Partners.

Business overview

BrainsWay develops advanced noninvasive neurostimulation treatments for mental health disorders, leveraging its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology. The company's core technology, based on patents filed by the US National Institutes of Health (NIH) and BrainsWay, is designed to improve health and transform lives. BrainsWay serves the healthcare industry, with current indications including major depressive disorder, obsessive-compulsive disorder (OCD), and smoking addiction. It operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In September 2024, BrainsWay announced a significant US$20 million private placement with Valor Equity Partners. This capital infusion signals strong investor confidence in BrainsWay's Deep TMS™ technology and its potential for continued growth and market penetration in the neurostimulation treatment space. The investment provides a clear runway for further development and expansion, reinforcing the company's strategic position in addressing mental health disorders.

Company Intelligence Q&A

What was a key financial development for BrainsWay in September 2024?

In September 2024, BrainsWay announced a US$20 million private placement with Valor Equity Partners.

When did BrainsWay receive FDA clearance for an accelerated Deep TMS protocol for Major Depressive Disorder?

In September 2025, BrainsWay received FDA clearance for an accelerated Deep TMS protocol for the non-invasive treatment of Major Depressive Disorder (MDD).

What strategic expansion did BrainsWay announce in October 2024?

In October 2024, BrainsWay announced further penetration into East Asia with the placement of 15 additional Deep TMS™ systems in Taiwan and South Korea.

What was a significant regulatory approval for BrainsWay in September 2024?

In September 2024, the Israel Ministry of Defense cleared BrainsWay Deep TMS™ for PTSD reimbursement at Israeli hospitals.

What strategic partnership did BrainsWay forge in September 2023?

In September 2023, BrainsWay forged a strategic partnership with a treatment provider in the Northeast U.S.